2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Ruthanna Davi

Session 11 – From Precision Medicine to Precision Health
Date: 24 July (Friday) 10:40 – 12:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Ruthanna Davi

Vice President, Data Science
Acorn AI by Medidata (a Dassault Systèmes company)



Ruthie Davi is a Statistician and Vice President, Data Science at Acorn AI by Medidata (a Dassault Systemes Company) and has a background in pharmaceutical clinical trials with more than 20 years working as a Statistical Reviewer, Team Leader, and Deputy Division Director in the Office of Biostatistics in CDER at FDA. At Acorn AI Ruthie is part of a team creating analytical tools to improve the efficiency and rigor of clinical trials, an example of which is the Synthetic Control work. Ruthie holds a Ph.D. in Biostatistics from George Washington University


Speech title & Synopsis

Synthetic Control Arms for Patient-Centric Efficient Drug Development

In some areas of clinical development, trials are failing at unacceptable rates. Historical clinical trials have emerged as attractive options to power synthetic controls that can aid in the replacement or augmentation of control groups. This session will highlight several case studies, including Medidata’s collaborations with Friends of Cancer Research, FDA, pharma representatives and others, on how Acorn AI’s Integrated Evidence solution, Synthetic Control Arm™, can support trial design and better understanding the effectiveness of a given therapy to create better value for the patients, regulators and payors.